In 2026, Modafinil continues to serve as a pivotal pharmaceutical tool for managing excessive daytime sleepiness. Known widely by its original brand name, Provigil, it is classified as a "eugeroic"—a wakefulness-promoting agent—that offers a cleaner alertness compared to traditional stimulants.